αvβ1 integrin-IN-1 (TFA)

αvβ1 integrin-IN-1 (TFA)

• UNSPSC Description: αvβ1 integrin-IN-1 TFA (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. Antifibrotic effects[1].
• Target Antigen: Integrin
• Type: Reference compound
• Related Pathways: Cytoskeleton
• Applications: Cancer-programmed cell death
• Field of Research: Cancer; Cardiovascular Disease
• Assay Protocol: https://www.medchemexpress.com/αvβ1-integrin-in-1-tfa.html
• Purity: 98.04
• Solubility: DMSO : 250 mg/mL (ultrasonic)|H2O : 5 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: O=C(O)[C@H](CC1=CC=C(NC(CCCCNC(N)=N)=O)C=C1)NC([C@H]2N(S(=O)(C3=CC=CC=C3)=O)CCC2)=O.OC(C(F)(F)F)=O
• Molecular Weight: 672.67
• References & Citations: [1]Reed NI, et al. Exploring N-Arylsulfonyl-l-proline Scaffold as a Platform for Potent and Selective αvβ1 Integrin Inhibitors. ACS Med Chem Lett. 2016 Aug 30;7(10):902-907.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: No Development Reported